The diagnostics landscape for sexually transmitted infections

Overview

This document highlights the diagnostics available now to support scale-up and expanded access to screening to meet the growing testing demands in low- and middle-income countries (LMICs).

The focus of this landscape is on the technologies (tests, platforms and systems for use in resource-limited settings) commercially available at the time of publication for syphilis, chlamydia, gonorrhoea, trichomoniasis, mycoplasma, herpes, and human papillomavirus.

This document does not provide market assessments or pipelines for new technologies but recognizes the need for additional complimentary documents to support decision makers in prioritizing STI testing in LMICs. The target audience for this document is broad but includes mainly national program managers.